Clinical Trial

Perioperative Epidural Block and Dexamethasone in Pancreatic Cancer Surgery

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
Pancreatic cancer remains a devastating disease with an average 5-year survival rate of about 3-5%. Previous retrospective studies showed that perioperative epidural block and/or dexamethasone are associated with improved outcome after cancer surgery. This randomized trial aims to investigate the effect of perioperative epidural block and/or dexamethasone on long-term survival in patients following pancreatic cancer surgery.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2019-07-17; most recent amendment 2025-07-30.
Status change: Recruiting → Active, Not Recruiting 2025-07-30
Status change: Not Yet Recruiting → Recruiting 2019-09-10
Trial Details
NCT Number NCT04025840
Lead Sponsor Peking University First Hospital
Collaborators: Peking University Cancer Hospital & Institute, The Second Affiliated Hospital of Chongqing Medical University
Conditions Pancreatic Cancer, Surgery, Epidural Block, Dexamethasone, Overall Survival
Enrollment 260 participants
Start Date 2019-09-11
Primary Completion 2024-10-22 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2025-07-31